R&D Pipeline
Innovation R&D Pipeline
Potential of our proprietary technology platform to be expanded into more research and therapeutic areas in the near future.
Therapeutic Area Program Target Modality Indication Discovery Preclinical Phase l Phase ll
Oncology
ALK201 FGFR2b ADC GC, BC, NSCLC,& solid tumors
ALK202 EGFR/CMET Bispecific ADC NSCLC, CRC & solid tumors
ALK101 EGFR/CMET Bispecific Antibody NSCLC, CRC & solid tumors
ALKN204 EGFR/HER3 Bispecific ADC Solid Tumors
ALKN203 Undisclosed ADC Solid Tumors
Immunology
ALKN401 Undisclosed Bispecific Antibody IgG associated diseases
Leveraging our powerful technology platform to drive continuous expansion of innovative pipeline